Indication
Diffuse Midline
1 clinical trial
1 product
4 drugs
Clinical trial
Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH MedulloblastomaStatus: Completed, Estimated PCD: 2022-09-30
Drug
GemcitabineDrug
ribociclibProduct
sonidegibDrug
trametinibDrug
Filgrastim